This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alain Bron, MD; Erik A. Lippa, MD, PhD; Frans Gunning, MD; Claude Bénichou, MD; Pierre Lesure, MD; Daniel Sirbat, MD; Jean Royer, MD; Jacques Flament, MD; Coleen Clineschmidt; Deborah Panebianco, MS; Agnes Buntinx, MS; Françoise Brunner-Ferber, PhD; Jean-Luc George, MD; Erik Greve, MD

Arch Ophthalmol. 1991;109(1):50-53.

Abstract
• The multiple-dose twice-daily efficacy of the topical carbonic anhydrase inhibitor MK-927, a racemic compound, was compared with that of its pharmacologically more active S-enantiomer in a four-center, double-masked, randomized, placebo-controlled, parallel study of 1.8% sezolamide hydrochloride (MK-417), 2% MK-927, and placebo, given twice daily to 48 patients with bilateral primary open angle glaucoma or ocular hypertension and morning intraocular pressure greater than 24 mm Hg in both eyes following washout of ocular hypotensive medications. Parallel 10-hour modified diurnal curves were performed before the study and on day 14, with 4-hour curves on days 1 and 4. Both compounds demonstrated significant lowering of intraocular pressure at 8 AM, 12 hours following the evening dose, and through 10 and 6 hours following the 8 AM dose for sezolamide and MK-927, respectively. Morning trough (evening) activity as measured by mean percent change in intraocular pressure from prestudy was 9.2% for sezolamide and –11.1% for MK-927 (–13.5% and –9.6%); peak effect occurred 2 hours after dose administration and was –19.4% and –19.2% for sezolamide and MK-927, respectively. From 2 hours after dose administration, sezolamide consistently demonstrated a slightly greater decrease in intraocular pressure than MK-927; however, these differences were not statistically significant.

Author Affiliations
From the Departments of Ophthalmology, University of Besançon (Drs Bron and Royer), University of Nancy-Brabois (Drs Lesure, Sirbat, and George), and University of Strasbourg (Drs Bénichou and Flament), France; Departments of Clinical Research (Dr Lippa and Ms Clineschmidt), Clinical Pharmacology (Drs Buntinx and Brunner-Ferber), and Biostatistics (Ms Panebianco), Merck Sharp & Dohme Research Laboratories, West Point, Pa; and Glaucoma Center, Academic Medical Center, Amsterdam, the Netherlands (Drs Gunning and Greve).

Footnotes
Accepted for publication September 13, 1990.

Presented in part at the Association for Research in Vision and Ophthalmology Annual Meeting, Sarasota, Fla, May 1, 1989.

Reprint requests to Clinical Research, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486 (Dr Lippa).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor
Wilkerson et al.
Arch Ophthalmol 1993;111:1343-1350.
ABSTRACT  

Dose Response and Duration of Action of Dorzolamide, a Topical Carbonic Anhydrase Inhibitor
Lippa et al.
Arch Ophthalmol 1992;110:495-499.
ABSTRACT  

Topically Active Carbonic Anhydrase Inhibitors for Glaucoma
Podos and Serle
Arch Ophthalmol 1991;109:38-40.
ABSTRACT